Phase II trials of the vaccine are expected to begin in 1996 in cystic fibrosis and chronic bronchitis patients. * Corvas International Inc., of San Diego, said preclinical studies of its thrombin inhibitor, which is derived from proteins produced by blood-feeding hookworms (ancylostoma caninum), showed the compound was effective and safe as an anti-blood- clotting drug...The buy-out is valued at between $12.50 to $13 per share...Phase II trials of TP10 are expected to begin in 1996 for adult

The drug is designed to bind to the CD2 receptor on the surface of immune system T cells. * Carrington Laboratories Inc., of Irving, Texas, signed an agreement with Mexico-based Laboratorios PiSA S.A...Phase II trials of TP10 are expected to begin in 1996 for adult respiratory distress syndrome. (c) 1997 American Health Consultants

The new company, which will focus on late-stage development and commercialization of new and formulated products in Asia, is 40 percent owned by Genelabs, 35 percent by the Taiwan government and 25 percent by private investors. (See BioWorld Today, July 18, 1995, p. 1.) * Guilford Pharmaceuticals Inc., of Baltimore, licensed rights to a biodegradable polymer from Yissum Research Development Corp...of the Hebrew University of Jerusalem, which it intends to develop for the delivery of drugs for

The work will broaden the company's gene therapy program for cancer by allowing in vivo administration of genes. * CoCensys Inc., of Irvine, Calif., completed a Phase I trial that showed ACEA 1021, a glycine-site N-Methyl- D-Aspartate receptor antagonist for stroke, was well tolerated and had no side effects. * Neurex Corp., of Menlo Park, Calif., said a Phase I/II study of SNX-111 for severe pain in seven patients showed the agent has potential to provide symptomatic relief in those who had

Serious infections occurred in 5 of 29 (17 percent) of infants given Leukine compared to 12 of 31 (39 percent) in the placebo group. * ImmunoGen Inc., of Cambridge, Mass., hired PaineWebber Inc., of New York, to help it achieve its partnering objectives. * IMRE Corp., of Seattle, said the FDA conditionally approved a 268-patient pivotal trial of its Prosorba column for the treatment of rheumatoid arthritis. * NeXstar Pharmaceuticals Inc., of Boulder, Colo., acquired patent rights to MiKasome

The company is developing non- absorbed, polymer-based drugs that selectively bind to and eliminate substances from the intestinal tract. * Immunex Corp., of Seattle, said it was served with two lawsuits from shareholders in connection with the buyout offer from American Home Products Corp., of Madison, N.J. Among the allegations is that the $14.50-per-share buyout price is too low. (See BioWorld Today, Nov. 3, 1995, p. 1.) * Innovir Laboratories Inc., of New York, entered into a research

The shares were sold to private and institutional investors. * Texas Biotechnology Corp., of Houston, started its second Phase III study of Novastan for heparin-induced thrombocytopenia and thrombosis syndrome...It's a randomized, double-blind 300-patient trial comparing the drug to ancrod, an anti-thrombotic. (c) 1997 American Health Consultants

Guilford will sell Gliadel to Orion and receive milestone and other payments. * InSite Vision Inc., of Alameda, Calif., which is developing eyedrop-based drug delivery technology, is restructuring to conserve cash...Procysteine is designed to replenish glutathione, which protects the body from reactive oxygen species. * Trinity Biotech, of Dublin, Ireland, raised $3 million in an offering to European institutional investors. (c) 1997 American Health Consultants

Rh's parent company, the Apotex Pharmaceutical Group, of Toronto, owns 85 percent of the new company. (See BioWorld Today, Aug. 1, 1995, p. 1.) * IBEX Technologies Inc., of Montreal, said a second Phase I study of Neutralase confirmed its ability to neutralize heparin in humans. * Parexel International Corp., a Boston-based contract research organization, said the Inter-Company Collabo- ration for AIDS Drug Development began its second research study _ one-year trials of 225 HIV patients in

Oncor Inc., of Gaithersburg, Md., said its premarket approval application for the in vitro diagnostic genetic test system for HER-2/neu will be reviewed Nov. 30, 1995, by an FDA advisory panel. * Ostex International Inc., of Seattle, entered into an agreement with SmithKline Beecham Clinical Laboratories, of Philadelphia, to market and sell its Osteomark test, which measures human bone loss, in the U.S. * Glyco Biomedical Ltd., of Novato, Calif., was awarded two grants totaling $127,000, one

felis bacteria is related to Helicobacter pylori, which is believed to be responsible for most peptic ulcers...plc, of Athlone, Ireland, agreed to pay Emisphere Technologies Inc., of Hawthorne, N.Y., $15 million in a joint venture aimed at combining Elan's drug delivery systems with Emisphere's membrane absorption technologies in the development of oral heparin

exclusive rights in Japan to its acylfulvenes, which are a family of cancer compounds completing preclinical studies...MGI could receive up to $12 million in precommercial milestones. * Neurobiological Technologies Inc., of Richmond, Calif., said a Phase II pilot study of Dynorphin A, a natural peptide, for relieving pain showed the drug was well-tolerated...Receptagen, which acquired Ryan in January 1994, sued the former shareholders, saying it agreed only to provide royalties of 5 percent on net

Shareholders will have until Dec. 28, 1995, to exercise the warrant...exclusive rights in Japan to its acylfulvenes, which are a family of cancer compounds completing preclinical studies...MGI could receive up to $12 million in precommercial milestones. (c) 1997 American Health Consultants

Pharmos Corp., of Alachua, Fla., said results were presented showing the neuroprotective activity of the HU- 211 in rats subjected to temporary focal forebrain ischemia...The neurological outcome of the ischemia was significantly improved in the drug group compared to vehicle...The company sold 2.85 million shares at $7 each in the IPO. * SunPharm Corp., of Jacksonville, Fla., signed a license agreement with the University of Florida Research Foundation Inc., of Gainesville, for rights to a process

Betaine is a naturally occurring substance thought to reduce homocysteine levels in the blood...Elevated amounts of homocysteine cause the rare, genetic disorder, which is linked to a number of complications, such as mental retardation, skeletal abnormalities and seizure disorders. * RiboGene Inc., of Hayward, Calif., was awarded a small business innovation research Phase II grant up to $750,000 to develop drugs for fungal infections. * Synsorb Biotech Corp., of Calgary, Alberta, was granted

The study will attempt to determine if the GC gene is reproduced in patients. * Orphan Medical Inc., of Minneapolis, submitted a new drug application to the FDA for Cystadane, or betaine anhydrous powder, to treat homocystinuria

Lisofylline is designed to inhibit production of phosphatidic acid and reduce oxidative damage to the lungs and other organs affected by ARDS. * Zonagen Inc., of The Woodlands, Tx., completed a sale of 598,850 shares of convertible preferred stock for $5.5 million in net proceeds

Alkermes Inc., of Cambridge, Mass., said underwriters for its recent public offering exercised their option to purchase 300,000 additional shares, bringing the offering to 2.3 million shares at $7 apiece. * Cambridge NeuroScience Inc., of Cambridge, Mass., registered to sell 1.2 million shares in a directed public offering of common stock

The court actions coincided with a recommendation for approval of Rorer's Taxotere, which is similar to Taxol, by the FDA's Oncologic Drugs Advisory Committee. * Helix BioMedix Inc., of Baton Rouge, La., said preclinical studies of its anti-infective compounds, called cytoporins, demonstrated they were effective in killing bacterial pathogens while not damaging healthy cells...The additional funds were generated through the sale of 497,000 shares to underwriters exercising options to cover